Houston, TXNCT04288726Now EnrollingIRB Ready

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Clinical Trial in Houston, TX

Access cutting-edge extranodal natural killer/t-cell lymphoma, nasal type treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Baylor College of Medicine

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access extranodal natural killer/t-cell lymphoma, nasal type specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related extranodal natural killer/t-cell lymphoma, nasal type treatment provided free

Apply for This Houston Location

Check if you qualify for this extranodal natural killer/t-cell lymphoma, nasal type clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Study in Houston

This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients

Sponsor: Baylor College of Medicine

Who Can Participate

Inclusion Criteria

Diagnosis and clinical course falling into one of the following categories:
Hodgkin lymphoma
Aggressive non-Hodgkin lymphoma
ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma
ALK-positive anaplastic T cell lymphoma
CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.
Age 12 to 75.
Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal.
AST 3 times or less than the upper limit of normal.
Estimated GFR \> 70 mL/min.
Pulse oximetry of \> 90% on room air
EKG shows no significant arrhythmias
Karnofsky or Lansky score of \> 60%.
Available allogeneic T cells with ≥15% expression of CD30CAR determined by flow-cytometry.
Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.

Exclusion Criteria

Received an investigational cell therapy or vaccine within the past 6 weeks.
Received an investigational small molecule drug within the past 2 weeks.
Received CD30 antibody-based therapy within the previous 4 weeks.
Received gemcitabine-containing chemotherapy within the previous 12 weeks
History of hypersensitivity reactions to murine protein-containing products.
Pregnant or lactating.
Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).
Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone.
Active significant, uncontrolled bacterial, viral or fungal infection.
Symptomatic cardiac disease (NYHA Class III or IV disease).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT04288726) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Treatment Options in Houston, TX

If you're searching for extranodal natural killer/t-cell lymphoma, nasal type treatment options in Houston, TX, this clinical trial (NCT04288726) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced extranodal natural killer/t-cell lymphoma, nasal type specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all extranodal natural killer/t-cell lymphoma, nasal type clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Houston, TX

See all lymphoma clinical trials recruiting in Houston — not just this study.

Browse Lymphoma Trials in Houston

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX